Yiran Gan 4/8/25 Yiran Gan 4/8/25 White matter alterations and their associations with biomarkers and behavior in subjective cognitive decline individuals: a fixel-based analysis Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Thickness, Annealing, and Surface Roughness Effect on Magnetic and Significant Properties of Co40Fe40B10Dy10 Thin Films Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Studying the Effects of Annealing and Surface Roughness on Both the Magnetic Property and Surface Energy of Co60Fe20Sm20 Thin Films on Si(100) Substrate Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Analyzer-to-Analyzer Variations in Assaying Ultralow Concentrated Biomarkers Associated with Neurodegenerative Diseases Using Immunomagnetic Reduction Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR) Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Concentration Dependency of Characteristic Times in the Reactions between Protein and Antibody-functionalized Magnetic Nanoparticles via Immunomagnetic Reduction Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Vascular risk factors and astrocytic marker for the glymphatic system activity Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease Read More Newer Posts Older Posts
Yiran Gan 4/8/25 Yiran Gan 4/8/25 White matter alterations and their associations with biomarkers and behavior in subjective cognitive decline individuals: a fixel-based analysis Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Thickness, Annealing, and Surface Roughness Effect on Magnetic and Significant Properties of Co40Fe40B10Dy10 Thin Films Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Studying the Effects of Annealing and Surface Roughness on Both the Magnetic Property and Surface Energy of Co60Fe20Sm20 Thin Films on Si(100) Substrate Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Analyzer-to-Analyzer Variations in Assaying Ultralow Concentrated Biomarkers Associated with Neurodegenerative Diseases Using Immunomagnetic Reduction Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR) Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Concentration Dependency of Characteristic Times in the Reactions between Protein and Antibody-functionalized Magnetic Nanoparticles via Immunomagnetic Reduction Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Vascular risk factors and astrocytic marker for the glymphatic system activity Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease Read More
